Here's Why You Should Buy Integer Holdings (ITGR) Stock Now

An image of a pencil and a calculator
Credit: Shutterstock photo

Integer Holdings CorporationITGR has been gaining investors' confidence on continued positive results. Over the past year, the company's stock has outperformed its industry . The stock has gained 53.8% against the industry's 2.5% fall and the S&P 500's 12.2% decline.

This renowned manufacturer and developer of medical devices and components, primarily for original equipment manufacturers (OEMs), has a market cap of $2.27 billion.

With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick for investors at the moment.

What's Working in Favor of the Stock?

Operational Excellence

As a result of continued efforts to streamline operations, Integer Holdings has been registering strong profits over the last couple of quarters. At the end of the third quarter of 2018, Integer Holdings delivered $305.1 million in sales, up 7% from last year on both a reported and organic basis. The company also registered high single-digit growth across all segments in the quarter.

Solid Foothold in the Broader MedTech Space

Integer Holdings has a stable footing in the cardiac, neuromodulation, orthopedics, vascular and advanced surgical markets. The company also has a presence in the non-medical power solutions market. Its brands include Greatbatch Medical, Lake Region Medical and Electrochem. Its primary customers include large, multi-national OEMs and their affiliated subsidiaries.

In the third quarter of 2018, Integer Holdings focused its sales efforts on increasing the market penetration in the higher growth Cardio & Vascular, Neuromodulation and Non-Medical Electrochem markets. The company is also taking initiatives to maintain its leadership position in the cardiac rhythm management market.

Sale of AS&O

The growth trajectory for Integer Holdings' Advanced Surgical and Orthopaedics unit (AS&O) has been strong. However, in a bid to strengthen the core unit, the company signed an agreement to divest the segment to MedPlast, LLC for $600 million. Management expects this deal to unlock significant value.

Other Key Picks

Other top-ranked stocks in the broader medical space are Genomic Health, Inc. GHDX , Surmodics, Inc. SRDX and Veeva Systems VEEV .

Veeva Systems' long-term earnings growth rate is estimated at 19.5%. The stock flaunts a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks here.

Genomic Health, with a Zacks Rank #1, has an earnings growth rate of 275% for the fourth quarter of 2018.

Integer Holdings, with a Zacks Rank #2, has an earnings growth rate of 31.2% for the first quarter of 2019.

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Veeva Systems Inc. (VEEV): Free Stock Analysis Report

Integer Holdings Corporation (ITGR): Free Stock Analysis Report

Surmodics, Inc. (SRDX): Free Stock Analysis Report

Genomic Health, Inc. (GHDX): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More